Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : January Effect 2005 -- Ignore unavailable to you. Want to Upgrade?

To: Q. who wrote (46)	1/7/2005 3:29:15 AM
From: TheLineMan	Respond to of 76

As a group my stock have gone from -8% to -3% (measuring from the last day since from Thanksgiving). I'm up way more, but that's hard to measure since I recycle profits back in through the first week or so of January. The collapse in the Nasdaq was an extra bonusfor my RYVNX QQQQ short positions. The one stock I still really like are MCHM. The stocks that are dragging me down are SOFO and SCLD (although by only a few pennies) ITRA and VITX were the scary ones but VITX did the mega jump today so I'm out. I allocated $100K to Jan trades and still have about $60K (but a lot of the cash is recycled from profits that occured from oportunistic sells) AGNT - never purchased APAC - bought 1.62 out 1.73 in again at 1.65 CRDS - bought 1.35 out 5% at 1.46 rebought positiion 1.35 FSTW - bought 1.95 sold 2.25 currently no position GGNS - bought 1.78 sold 1.99 currently no position (this one might just be a buy on the takeover someone might one to research it) INFO - bought 1.43 to 1.45 still holding at the end of Dec was up to $1.65 (I new to sell but I had already taken oprofits on a lot of stocks that day an decied to let this one ride) INOW in 1.10 to 1.15 out 1.24 looking to renter ITRA in 1.00 out 50% at 1.08 - (don't like this one -rel crap) MCHM - bought .68 sold .78 recycled at .70 sold at .80 in again at .70 (this one is year 3 for this stock) MPET - lowball orders never executed no position PRLS - lowball orders never executed no position (even though this mother is now below my Dec order (dont like this one real crap too) SCKT - in 1.68 average out 1.93 in again at 1.78 SCLD in at 1.89 still waiting( sold about 30% at 1.93 mainly because of weighting) SOFO - tons of this crap at 1.45 to 1.48 (probably overwighted) TIII in at 1.43 out 66% at 1.66 VASO in at .93 out .99 (did that one twice) Surged to 1.3 but no position (this is one that crops up every year) I did have order in at .93 again and it got close VITX bought this one 3 trimes and sold 3 times .68 to .86 .70 to .86 and .70 to 1.10 (75% gain Just today) VLFG in at 1.5 out 1.68 VMTI - bought at 1.07 sold VNWI - never bought

To: Q. who wrote (46)	1/11/2005 10:29:20 PM
From: Q.	Read Replies (1) \| Respond to of 76

Update on my results: As compared to Dec. 31: original portfolio: down 8.5% actual portfolio: down 7.3% Russell 2000: down 6.2% actual portfolio: PARS sold @ 1.25 Jan 4. Today was another down day in the ongoing correction, which is hitting small caps harder than blue chips. My best performer is at breakeve. That's LIPD. It put out an 8k today disclosing a letter to shareholders that touts the company's prospects. Here's an excerpt: Dear Stockholder: We expect that 2005 will be the year Lipid Sciences springboards from a pre-clinical stage company to being poised to launch a human clinical trial for our proprietary selective HDL delipidation technology. Why am I so bullish as we enter this new phase of your Company’s development? Today we have submitted a pre-Investigational Device Exemption packet to the Food and Drug Administration. That action positions us one step closer to our goal of the initiation of a human clinical trial for our HDL Therapy platform. The information submitted to the FDA is based on solid scientific data, which has been reviewed by our Scientific Advisory Board, that demonstrates that researchers have successfully used Lipid Sciences’ proprietary delipidation process to turn good cholesterol into great cholesterol and thus remove arterial plaque at a greater rate. Dr. Frank M. Sacks, Professor of Cardiovascular Disease Prevention, Harvard School of Public Health, and a member of Lipid Sciences’ Scientific Advisory Board, was invited to present the Company’s breakthrough selective delipidation data at the American Heart Association’s Scientific Session 2004, a major annual health conference that was held in November.